CRX.L Regulatory News (CRX)

17 Aug 2005 07:01

Cyprotex PLC17 August 2005 Press Release 17 August 2005 Cyprotex PLC Appointment of Chief Scientific Officer Cyprotex PLC (LSE: CRX), the drug discovery technology and information company,is pleased to announce the appointment of Dr Darwin Cheney as Chief ScientificOfficer of the Company with immediate effect. Dr Cheney will be responsible forall laboratory operations at Cyprotex. Dr. David Leahy, who held the positionpreviously, becomes Chief Technical Officer with specific responsibility for thedevelopment of new products and services for the Company. Dr Cheney has worked for many years in laboratory operations management asExecutive Director of Contract Research for In Vitro Technologies and asDirector of Neuroscience and Cardiovascular Research and Executive Director ofClinical Operations and Statistics at CIBA-GEIGY Pharmaceuticals. He haspublished 116 scientific papers and brings over 25 years' experience in thediscovery and development of pharmaceutical compounds. In the past year, Cyprotex has doubled its revenues and expanded its customerbase by several fold as it has gained recognition as a high quality provider ofinformation and technology to the Biotechnology and Pharmaceutical industry.Cyprotex uses both computational and experimental approaches to understand howcompounds are processed by the body. Commenting on the appointment, Robert Morrisson Atwater, Chief Executive Officerof Cyprotex PLC, said: "We are extremely fortunate to have the knowledge,experience and skills of Darwin. He brings a wealth of sector knowledge andcommercial expertise with him and I have no doubt he will play a pivotal role inthe growth of Cyprotex." - Ends - For further information: Cyprotex PLCRobert Morrisson Atwater, Chief Executive Officer Tel: +44 (0) 1625 505 100ir@cyprotex.com www.cyprotex.comCode Securities LimitedChris Collins Tel: +44 (0) 20 7024 2000cic@codesecurities.com www.codesecurities.com Media enquiries: Abchurch Communications LimitedHeather Salmond / Samantha Robbins Tel: +44 (0) 20 7398 7700samantha.robbins@abchurch-group.com www.abchurch-group.com Notes to editors Cyprotex plc - www.cyprotex.com Cyprotex is a specialist provider of experimental and computational capabilitiesto support ADME/toxicity and pharmacokinetics assessment for drug discoverypartners. Its core products include the Cloe Screen(TM) in vitro ADME/toxicityservice, and Cloe PK(TM) - a pharmacokinetics prediction system which integratescore ADME and physicochemical compound data to predict compound levels in plasmaand major organs in the body. This unique combination of technologies is aimedat improving pharmaceutical productivity by improving the quality of compoundlibraries and drug candidates progressing through the drug pipeline. Cyprotexis based in the UK and is listed on the London Stock Exchange (CRX). This information is provided by RNS The company news service from the London Stock Exchange